Precision Immunology: Targeting the Drivers of Immune Dysfunction
Overview of Scientific Approach
Our portfolio includes investigational therapies designed to target biologically validated pathways implicated in immune-mediated diseases.
Through clinical development programs, we are evaluating their potential to modulate disease-relevant mechanisms and address unmet medical needs.
We are advancing a broad pipeline of candidates across multiple indications, with the aim of generating scientific evidence that may support future treatment options for patients with serious diseases.
Programs
Program
Mechanism
Modality & Administration
Indication
Indication Stage
Preclinical
Early Clinical
Late Clinical
Afimetoran
TLR7/8 inhibitor
small molecule,
oral
oral
Systemic Lupus Erythematosus (SLE)
Late Clinical
Cutaneous Lupus Erythematosus (CLE)
Late Clinical
Lomedeucitinib
TYK2 inhibitor
small molecule,
oral
oral
Systemic Sclerosis (SSc)
Late Clinical
BLN-326
IL-2-CD25 fusion protein
biologic, IV/SC
Atopic Dermatitis
Early Clinical
Lupus
Early Clinical
BLN-481
Anti-IL-18Rb antibody
biologic, IV/SC
Undisclosed indications
Preclinical
BLN-498
Myeloid-selective IL‑10
biologic, IV/SC
Undisclosed indications
Preclinical
Full Pipeline
For additional information on Beeline Medicines’ pipeline, please visit our corporate website.